Myriad has discontinued the development of Flurizan.

Open-label treatment with MPC-7869 for participants in a previous randomized study.

Inclusion Criteria:

• Participation in a previous MPC-7869 randomized protocol
• Have had a diagnosis of probable Alzheimer's disease.
• Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
• Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
• Female subjects must be surgically sterile or postmenopausal for > 1 year.
• Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.

Exclusion Criteria:

• History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
• Chronic or acute renal, hepatic or metabolic disorder.
• Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.